Flexion picks up two more bullish ratings

Wells Fargo initiates coverage of Flexion Theapeutics (FLXN) with an Outperform rating with a price target of $24 - $26 citing positive Phase 2 trial results of its lead product, FX006, a sustained-release injectable steroid for osteoarthritis pain.

Needham & Co. initiates coverage with a Buy rating and $26 price target.

The stock debuted on February 12.

Shares currently exchange hands at $19.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs